CTLA4 and neoplasm: Notably, in groups receiving TTFields alongside anti-PD-1/anti-CTLA-4 or anti-PD-L1, there was a pronounced increase in immune cell infiltration, particularly cytotoxic T cells, into the tumor microenvironment20.